secwatch.observer — SEC 8-K summary
======================================

Issuer:     Y-mAbs Therapeutics, Inc. (—)
CIK:        0001722964
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001104659-23-000896
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Y-mAbs restructures after FDA CRL; cuts workforce 35%, 2023 revenue guidance $60-65M
--------------------------------------------------------------------------------

- Workforce reduction of ~35%; estimated restructuring charges of $5.0M including $3M severance and $2M stock-based comp.
- 2023 operating expenses guided to $115-120M, a 28% reduction vs. prior 2022 guidance of $162-167M.
- Cash runway extended into Q1 2026; estimated 2023 cash burn $50-55M on year-end cash of ~$106M.
- DANYELZA net product revenue expected $60-65M in 2023, up from ~$47-48M in 2022.
- Deprioritizes omburtamab, GD2-GD3 vaccine, and CD33 bispecific constructs after FDA CRL.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1722964/000110465923000896/0001104659-23-000896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1722964/000110465923000896/tm231596d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-000896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer